7-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-2,3-二氢苯并[b]呋喃 | 934586-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 7-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-2,3-二氢苯并[b]呋喃
• 中文别名: 2,3-二氢苯并呋喃-7-硼酸频哪醇酯
• 英文名称: 7-( 4,4,5,5-tetra methyl-[1,3,2]dioxaborola n-2-yl)-2,3-dihydro-benzofuran
• 英文别名: 2-(2,3-dihydrobenzofuran-7-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane；2-(2,3-dihydro-1-benzofuran-7-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane
• CAS: 934586-50-2
• 化学式: C₁₄H₁₉BO₃
• 分子量: 246.114
• InChiKey: HCAAUTYLSSDHFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2,3-Dihydrobenzofuran-7-boronic acid, pinacol ester
Synonyms: 7-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzo[b]furan

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2,3-Dihydrobenzofuran-7-boronic acid, pinacol ester
CAS number: 934586-50-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H19BO3
Molecular weight: 246.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  7-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-2,3-二氢苯并[b]呋喃 在 四(三苯基膦)钯 、 potassium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  안트라센 유도체 화합물 및 이를 포함하는 유기전계발광소자

  摘要：

  本发明涉及一种新型有机电致发光化合物，其特征在于其为化合物，其表示为[化学式1]至[化学式2]，根据本发明的有机电致发光化合物具有高玻璃化转变温度，具有优异的热稳定性，并且当将其应用于有机电致发光器件时，可以实现低驱动电压、高亮度、高色纯度和长寿命的有机电致发光器件。 [化学式1] [化学式2]

  公开号：

  KR102121583B1
• 作为产物：
  描述：

  2,6-二溴苯酚 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 正丁基锂 、 potassium acetate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 正己烷 、 水 、 甲苯 为溶剂， 反应 0.5h， 生成 7-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)-2,3-二氢苯并[b]呋喃
  参考文献：
  名称：

  안트라센 유도체 화합물 및 이를 포함하는 유기전계발광소자

  摘要：

  本发明涉及一种新型有机电致发光化合物，其特征在于其为化合物，其表示为[化学式1]至[化学式2]，根据本发明的有机电致发光化合物具有高玻璃化转变温度，具有优异的热稳定性，并且当将其应用于有机电致发光器件时，可以实现低驱动电压、高亮度、高色纯度和长寿命的有机电致发光器件。 [化学式1] [化学式2]

  公开号：

  KR102121583B1

文献信息

• [EN] IMIDAZO [1, 2 - B] PYRIDAZINE - BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND USES THEREOF<br/>[FR] COMPOSÉS À BASE D'IMIDAZO [1, 2-B] PYRIDAZINE, COMPOSITIONS LES COMPRENANT ET UTILISATIONS DE CEUX-CI
  申请人：LEXICON PHARMACEUTICALS INC

  公开号：WO2013134219A1

  公开（公告）日：2013-09-12

  Imidazo[1,2-b]pyridazine-based compounds of the formula (I): are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  基于咪唑并[1,2-b]吡啶嗪的化合物的公式（I）被披露，其中R1、R2和R3在此处被定义。还披露了包含这些化合物的组合物以及它们用于治疗、管理和/或预防由适配器相关激酶1活性介导的疾病和紊乱的方法。
• FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF
  申请人：GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD.

  公开号：US20180208604A1

  公开（公告）日：2018-07-26

  Disclosed area fused ring pyrimidine compound, and an intermediate, a preparation method, a composition and a use thereof. The fused ring pyrimidine compound is a compound as shown in formula I, a tautomer, an enantiomer, a diastereoisomer, a pharmaceutically acceptable salt, a metabolite, a metabolic precursor or a prodrug thereof, wherein the above-mentioned compound is used for the preparation of a medicine for preventing, remitting or treating one or more of immune system diseases, autoimmune diseases, cell proliferative diseases, allergic disorders and cardiovascular diseases, and the compound has a strong inhibitory effect on the Janues kinase, FGFR kinase, FLT3 kinase and Src family kinase.

  揭示的区域融合环嘧啶化合物，以及中间体、制备方法、组合物及其用途。融合环嘧啶化合物是如下式I所示的化合物，其为互变异构体、对映异构体、顺反异构体、药学上可接受的盐、代谢物、代谢前体或其前药，上述化合物用于制备用于预防、缓解或治疗免疫系统疾病、自身免疫疾病、细胞增殖性疾病、过敏性疾病和心血管疾病中的一种或多种的药物，且该化合物对Janues激酶、FGFR激酶、FLT3激酶和Src家族激酶具有强烈的抑制作用。
• <i>Ortho</i>-Selective C–H Borylation of Aromatic Ethers with Pinacol-borane by Organo Rare-Earth Catalysts
  作者：Can Xue、Yong Luo、Huailong Teng、Yuanhong Ma、Masayoshi Nishiura、Zhaomin Hou

  DOI：10.1021/acscatal.8b01364

  日期：2018.6.1

  borylation of aromatic ethers such as anisoles is of much interest and importance, but has remained a challenge to date. We report herein the catalytic ortho-selective C–H borylation of a wide range of aromatic ethers with pinacolborane (HBpin) by rare-earth metallocene complexes. This protocol offers an efficient and straightforward route for the synthesis of a variety of borylated aromatic ether derivatives

  芳族醚（如茴香醚）的区域选择性C–H硼化非常令人关注和重要，但迄今为止仍是一个挑战。我们在这里报告了稀土金属茂配合物与频哪醇硼烷（HBpin）催化的各种芳族醚的邻位选择性C–H硼化反应。该方案为合成各种硼酸化的芳族醚衍生物提供了一种有效而直接的途径。发现用于稀土金属催化剂的合适的金属/配体组合对于促进这种转化至关重要。
• SUBSTITUTED 4-ARYL-N-PHENYL-1,3,5-TRIAZIN-2-AMINES
  申请人：Lücking Ulrich

  公开号：US20140045852A1

  公开（公告）日：2014-02-13

  The present invention relates to substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines of general formula (I) as described and defined herein, and methods for their preparation, their use for the treatment and/or prophylaxis of disorders, in particular of hyper-proliferative disorders and/or virally induced infectious diseases and/or of cardiovascular diseases. The invention further relates to intermediate compounds useful in the preparation of said compounds of general formula (I).

  本发明涉及一般式（I）所描述和定义的取代的4-芳基-N-苯基-1,3,5-三嗪-2-胺，以及它们的制备方法，它们用于治疗和/或预防疾病，特别是高增殖性疾病和/或病毒感染性疾病和/或心血管疾病。本发明还涉及在制备所述一般式（I）化合物中有用的中间体化合物。
• Imidazo[1,2-b]pyridazine-based compounds, compositions comprising them, and methods of their use
  申请人：Bi Yingzhi

  公开号：US08969565B2

  公开（公告）日：2015-03-03

  Imidazo[1,2-b]pyridazine-based compounds of the formula: are disclosed, wherein R1, R2 and R3 are defined herein. Compositions comprising the compounds and methods of their use to treat, manage and/or prevent diseases and disorders mediated by mediated by adaptor associated kinase 1 activity are also disclosed.

  公开了基于咪唑并[1,2-b]吡啶的化合物的公式：其中R1，R2和R3在此定义。还公开了包含该化合物的组合物以及使用它们治疗、管理和/或预防适配器相关激酶1活性介导的疾病和紊乱的方法。